KalVista Pharmaceuticals, Inc. Common Stock (KALV) is a publicly traded Healthcare sector company. As of May 20, 2026, KALV trades at $26.77 with a market cap of $1.42B and a P/E ratio of -7.25. KALV moved +0.00% today. Year to date, KALV is +73.16%; over the trailing twelve months it is +121.79%. Its 52-week range spans $7.30 to $26.85. Analyst consensus is neutral with an average price target of $29.17. Rallies surfaces KALV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Halper Sadeh Challenges KalVista’s $27 Cash Deal, Seeks Higher Consideration: Halper Sadeh LLC is investigating KalVista Pharmaceuticals’ sale to Chiesi Group for $27 per share in cash, alleging potential breaches of fiduciary duty and terms that may restrict competing offers. Shareholders could seek increased consideration or additional disclosures on a contingent fee basis, with no upfront legal costs.
| Metric | Value |
|---|---|
| Price | $26.77 |
| Market Cap | $1.42B |
| P/E Ratio | -7.25 |
| EPS | $-3.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.85 |
| 52-Week Low | $7.30 |
| Volume | 7.34M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-183.44M |
| Gross Margin | 0.00% |
8 analysts cover KALV: 0 strong buy, 2 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $29.17.